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A transcriptome-wide association 
study based on 27 tissues identifies 
106 genes potentially relevant for 
disease pathology in age-related 
macular degeneration
tobias Strunz1,105, Susette Lauwen2,3,105, Christina Kiel1,105, International AMD Genomics 
Consortium (IAMDGC)4,†, Anneke den Hollander2,3 & Bernhard H. f. Weber1*
Genome-wide association studies (GWAS) for late stage age-related macular degeneration (AMD) 
have identified 52 independent genetic variants with genome-wide significance at 34 genomic loci. 
Typically, such an approach rarely results in the identification of functional variants implicating a 
defined gene in the disease process. We now performed a transcriptome-wide association study 
(TWAS) allowing the prediction of effects of AMD-associated genetic variants on gene expression. The 
TWAS was based on the genotypes of 16,144 late-stage AMD cases and 17,832 healthy controls, and 
gene expression was imputed for 27 different human tissues which were obtained from 134 to 421 
individuals. A linear regression model including each individuals imputed gene expression data and 
the respective AMD status identified 106 genes significantly associated to AMD variants in at least one 
tissue (Q-value < 0.001). Gene enrichment analysis highlighted rather systemic than tissue- or cell-
specific processes. Remarkably, 31 of the 106 genes overlapped with significant GWAS signals of other 
complex traits and diseases, such as neurological or autoimmune conditions. Taken together, our study 
highlights the fact that expression of genes associated with AMD is not restricted to retinal tissue as 
could be expected for an eye disease of the posterior pole, but instead is rather ubiquitous suggesting 
processes underlying AMD pathology to be of systemic nature.
Age-related macular degeneration (AMD) is a frequent disease of the choroid, Bruch’s membrane, retinal pigment 
epithelium and photoreceptor complex characterized by a progressive loss of vision in older individuals of indus-
trialized countries. For the year 2016, it was estimated that worldwide approximately 162 million were affected 
by early AMD (prevalence 8.0%) and 10 million people by late AMD (prevalence 0.4%). These numbers were 
predicted to increase to 260 million patients with early and 19 million with late AMD by the year 20401.
It is well established that AMD is a complex disease, involving environmental and genetic risk factors. The 
International AMD Genomics Consortium (IAMDGC) performed a genome-wide association study (GWAS) 
and reported 7,218 genetic variants to be associated with late-stage AMD at a genome-wide significance level 
(P-value ≤ 5 × 10−8). Sequential forward selection finally identified 52 independent association signals, which are 
distributed over 34 genomic loci2. An additional 11,768 variants (P-value ≤ 5 × 10−4) failed to reach genome-wide 
significance in this study but may well play a role in AMD pathogenesis. These variants may become relevant only 
with an increase in sample-size in future GWAS, or by gathering additional information on the functional impact 
of these variants in relation to AMD pathology.
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Typically, GWAS rarely point to genetic variants with a clear functional impact on cellular integrity, particu-
larly since the majority of genetic variants identified by GWAS are located in non-coding, intronic or intergenic 
regions of the genome. However, the latter variants in particular may play an important role in regulating gene 
expression3. An attractive approach to overcome such limitations of GWAS is to correlate the disease-association 
of single variants with mRNA expression in a given tissue utilizing large-scale mRNA expression studies. Such 
analyses result in data known as expression quantitative trait loci (eQTL)4.
Generally, eQTL are calculated in healthy tissues to identify genes whose expression is regulated by genetic 
variation which, in turn, may be useful to further understand disease etiology based on the concurrence of GWAS 
signals and genetic variation altering gene expression. At present, two studies explored single tissue eQTL in the 
context of AMD by investigating liver5 and retinal6 tissue. These approaches successfully identified eQTL in liver 
for five AMD loci, and in retina for nine of the 34 AMD-associated loci (Q-value ≤ 0.05). However, for the major-
ity of variants the causative signal remains elusive. Evaluation of local eQTL in the context of complex diseases 
usually includes only the lead variant of a disease-associated locus as linkage disequilibrium (LD) and haplotype 
structures complicate the analysis. For AMD, a total of 7,218 variants would need to be investigated, which leads 
to a high burden for multiple testing potentially obscuring real biological signals.
To overcome the limitations of single eQTL analysis, a promising approach was established and is known as 
transcriptome wide association study (TWAS). In TWAS more complex models than least squares linear regres-
sion are applied. These typically include models used in classical machine learning, such as ridge regression, 
lasso regression, or elastic net, and aim to determine a set of genetic variants which consistently influence gene 
expression in a given tissue. In a further step, these variants are extracted from classical GWAS datasets to predict 
their influence on relative gene expression eventually relevant to disease processes. Thus, correlating imputed 
gene expression to disease status appears to be appropriate to identify disease-associated genes7–9. It should be 
noted however that TWAS are not suited to extract information on gene expression alterations at the time of 
disease manifestation as the model building solely includes gene expression determined in healthy tissue. As a 
major feature, TWAS need less correction for multiple testing than eQTL analysis, mainly due to the fact that the 
calculations are based on several thousand genes instead of usually seven to twelve million genetic variants. In 
addition, TWAS involve potential combinatory effects of genetic variants, an invaluable benefit over approaches 
using simple single genetic variant models.
Gamazon et al. (2015) proposed a gene-based association method termed PrediXcan to perform TWAS based 
on data of the Genotype-Tissue Expression (GTEx) project and respective individual genotype information from 
GWAS studies8,10. The required prediction model weights of up to 48 different tissues can be downloaded through 
the website PredictDB (http://predictdb.org). TWAS based on individual genotypes identify disease-associated 
genes in known loci from GWAS, and also include genomic regions, which were initially not disease-associated 
as they did not reach genome-wide significance. This way, TWAS permit the detection of novel disease-associated 
genes.
TWAS data derived from various tissues are especially valuable for complex diseases with unknown under-
lying pathomechanisms. Although AMD pathology appears restricted to the posterior pole of the eye, several 
studies have highlighted systemic effects of AMD-associated genes11–15. To this effect, previous studies revealed 
a significant association of late-stage AMD with the genetic risk of 16 seemingly unrelated complex traits and 
diseases including psoriasis, rheumatoid arthritis and systemic lupus erythematosus as well as blood lipid levels16.
To identify potentially differential expressed genes in AMD cases compared to controls, we performed a TWAS 
based on the individual level imputed expression data of 33,976 individuals and included models derived from 
27 human tissues.
Results
Identification of genes associated with AMD genetics. The main objective of this study is to identify 
potentially relevant genes in AMD etiology. To this end, we conducted a TWAS based on the IAMDGC data-
set2 and applied the PrediXcan8 algorithm based on genotype and phenotype data from 16,144 late-stage AMD 
cases (including clinical diagnoses of geographic atrophy and/or choroidal neovascularization), and from 17,832 
AMD-free controls. The prediction models from 27 tissues were retrieved via PredictDB (number of samples per 
tissue between 134 and 421) and were implemented into our analysis. We imputed gene expression for each tissue 
separately and applied a linear regression model to identify late-stage AMD-associated genes based on the AMD 
status of each individual. After correction for multiple testing, we considered genes with a Q-value smaller than 
0.001 to be significantly associated with AMD in the corresponding tissue (Supplementary Fig. 1). This stringent 
threshold was chosen to avoid false positive results. In each tissue, a minimum of 11 (see “Brain Cerebellum” and 
“Heart Left Ventricle”) and up to 28 (see “Adipose Subcutaneous” and “Nerve Tibial”) AMD-associated genes 
(Fig. 1 and Supplementary Table S1a,b) were identified (mean 17.63; SD 5.02). Altogether, 106 unique genes were 
significantly associated to AMD in at least one tissue. Of these, 88 genes are located in loci that are known to be 
AMD-associated with genome-wide significance (Table 1 and Supplementary Table S1c)2. Moreover, 18 addi-
tional genes were not located in proximity (window size of 1MB) to any of the 52 independent hits identified by 
Fritsche et al. (2016), and may represent novel AMD loci (Table 2).
Positive effect sizes point to predicted gene expression in healthy tissue being higher in AMD cases than con-
trols, whereas negative effect sizes are indicative of decreased gene expression. The largest effect sizes ranged from 
−0.38 (ARMS2, Testis) to +0.35 (CFHR1, Liver). The mean absolute effect size across all AMD-associated genes 
(Supplementary Table S1b) was 0.035 (SD: 0.039). Four of the 106 genes showed remarkably higher absolute effect 
sizes in comparison to the remaining genes. These include the CFH-related genes CFHR1, 3 and 4 (positive effect 
sizes; higher gene expression in cases compared to controls) and ARMS2 (negative effect size; lower gene expres-
sion in cases compared to controls). Notably, ARMS2 gene expression is AMD-associated in all 14 predictable 
tissues, with a mean effect size of −0.098 (SD: 0.09) (Supplementary Table S1c).
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Interestingly, 54 of the 106 genes were significantly AMD-associated in more than one of the 27 tissues inter-
rogated. Sixteen genes (ADAM19, ARMS2, BTBD16, CFH, CFHR1, CFHR3, GPR108, PILRA, PILRB, PLA2G12A, 
PLEKHA1, PMS2P1, PPIL3, RDH5, STAG3L5P, and TNFRSF10A) were associated with AMD disease status 
in over 10 tissues, pointing to effects likely acting in systemic processes. Moreover, the predicted gene expres-
sion of three genes (PILRA, PILRB, and STAG3L5P) located within known AMD Locus 112 was significantly 
AMD-associated in nearly all tissues analyzed (Supplementary Table S1c). A total of 52 out of 106 genes were 
significantly AMD-associated in only one of the 27 tissues analyzed.
To further validate these findings, we tested the variants used for prediction of gene expression for their 
genome-wide significant association with AMD status. This analysis was performed for each gene-tissue pair 
of the 106 AMD-associated genes separately to allow for tissue dependency of the imputation models in gene 
expression (Supplementary Table S1b). Many of the identified genes, which are located in loci known to be 
AMD-associated with genome-wide significance2, were associated with AMD status in several tissues. To facil-
itate interpretation, we had a detailed look at the prediction models of the tissues, which showed the highest 
absolute effect sizes (“strongest effect tissue”) for each of the corresponding 88 genes. We observed that 66 of 88 
genes harbor at least one genome-wide significant AMD-GWAS variant (Supplementary Table S1c). Interestingly, 
only for a single gene (KCNT2), all of the prediction model variants are also significantly associated with AMD. 
For 49 of the 66 genes less than 50% of the prediction model variants were AMD-associated with genome-wide 
significance. We further investigated if any of the prediction model variants for the 22 remaining genes showed a 
weak AMD-association signal in the GWAS of Fritsche et al. (GWAS P-value < 1 × 10−04)2. This was the case for 
20 genes, leaving AC006273.5 (“Skin not sun exposed suprapubic”) and ZKSCAN1 (“Artery aorta”), which did not 
include any potentially AMD-associated variant (Supplementary Table S1b).
Moreover, we analyzed whether the 18 of 106 AMD-associated genes which are located in novel AMD loci, 
included variants with a sub-threshold AMD-association signal for gene expression prediction. This was true 
for 12 genes showing P-values below the threshold for suggestive association in the latest AMD GWAS (GWAS 
P-value < 1 × 10−04)2 (Table 2).
Network analysis of the 106 genes associated with AMD. To further explore the biological function 
of the 106 genes found to be associated with AMD status in this study, we performed an enrichment analysis 
based on gene ontology (GO) terms (Supplementary Table S2a). For 17 genes, no GO terms were found and no 
function had been assigned to the genes so far. This latter group contains eight pseudogenes, five long non-coding 
RNAs, and four protein coding genes (Supplementary Table S2b). The other 89 genes are involved in a variety 
of biological pathways, of which eight are significantly enriched (adjusted P-value < 0.05). All eight significantly 
enriched pathways are related to either the complement pathway or to lipid related processes (Fig. 2). Remarkably, 
Figure 1. TWAS results for 27 tissues. A TWAS was conducted based on the genotypes of 16,144 late-stage 
AMD cases and 17,832 AMD-free controls. Prediction models of 27 tissues were included in the analysis. The 
schematic overview demonstrates the number of significant AMD-associated genes (FDR < 1 × 10−3) within 
the respective tissue. If a gene was found exclusively in a single tissue, it was marked as tissue-specific (TS). 
Tissue classification was performed manually according to main functions or metabolic assignments. Adipose 
SU: Adipose Subcutaneous; Adipose VO: Adipose Visceral Omentum; Artery AO: Artery Aorta; Artery TI: 
Artery Tibial; Brain CE: Brain Cerebellum; Breast MT: Breast Mammary Tissue; Cells TF: Cells Transformed 
fibroblasts; Colon SI: Colon Sigmoid; Colon TR: Colon Transverse; Esophagus GJ: Esophagus Gastroesophageal 
Junction; Esophagus MC: Esophagus Mucosa; Esophagus MS: Esophagus Muscularis; Heart AA: Heart Atrial 
Appendage; Heart LV: Heart Left Ventricle; Muscle SK: Muscle Skeletal; Nerve TI: Nerve Tibial; Skin NSS: Skin 
Not Sun Exposed Suprapubic; Skin SEL: Skin Sun Exposed Lower leg.
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we found two novel genes associated with AMD status acting in the complement pathway, namely CD55 and 
CR2, next to five complement genes in already established AMD loci (CFH, CFHR1, CFHR3, CFHR4, CFI)2. The 
enrichment of genes in lipid related processes is reflected by genes such as CETP, LIPC, PLTP and ABCA7.
Comparison to AMD TWAS of retinal tissue. GTEx reveals no data entries for eye tissues. Recently, 
Ratnapriya et al. (2019) calculated eQTL based on 406 retinal tissue samples, the majority of which were 
from AMD cases and only around 100 samples from controls. Based on these data, they performed a TWAS 
using the summary statistics of Fritsche et al. (2016)2,6,7 and identified 31 significantly AMD-associated genes 
(Q-value ≤ 0.001, genetic model R2 ≥ 0.01) (Supplementary Table S3). We compared these with our results from 
the present study to identify potential retina-specific effects. Nine of the 31 genes from Ratnapriya et al. (2019) 
were located within the MHC locus and thus were omitted from our further comparisons. Another 16 genes 
were AMD-associated in at least one of the 27 tissues within our study and therefore do not appear to reflect 
retina-specific effects. Furthermore, most of these 16 genes show the same effect direction in retina as in the other 
tissues tested in our study. There are two exceptions: (1) In retina, the predicted gene expression of HTRA1 was 
significantly lower in AMD cases than controls. This was also the case for the two tissues “Esophagus Mucosa” and 
“Esophagus Gastroesophageal Junction” in our study. In contrast, predicted HTRA1 expression was significantly 
higher in AMD cases than controls in five tissues (see “Thyroid”, “Skin Sun Exposed Lower leg”, “Heart Atrial 
Appendage”, “Pituitary”, and “Testis” in Supplementary Table S1b). (2) Ratnapriya et al. (2019) predict PLA2G12A 
gene expression to be lower in AMD cases compared to controls in retinal tissue. In our study, PLA2G12A was 
predictable in 15 out of 27 tissues and significantly AMD-associated in 13 of these. In each of these 13 tissues gene 
expression of PLA2G12A is predicted to be consistently higher in AMD cases compared to controls.
To summarize the retinal findings, six genes were AMD-associated exclusively in retina, but not in any of the 
27 tissues investigated in our study. Among these, the long non-coding RNA STAG3L5P-PVRIG2P-PILRB and 
the uncharacterized gene RP11-644F5.10 (ENSG00000258311) were not measured within the GTEx dataset and 
therefore no conclusions can be drawn. The remaining four genes are expressed in several GTEx tissues, but were 
not AMD-associated in our study. MEPCE is a protein coding gene located on chromosome 7, and is known to 
be a 7SK methylphosphate capping enzyme17. Another gene, RLBP1, encodes the cellular retinaldehyde-binding 
AMD locusa Locus namea Chr
AMD-associated genes in TWAS analysisb (Number of significant tissues (FDR < 0.001) and 
effect direction within tissues)c
1 CFH 1 CFHR3 (20+); CFHR1 (14+); CFH (10−/1+); KCNT2 (6−); ZBTB41 (5+); CFHR4 (2+); F13B (1+); ASPM (1+); RP11.332L8.1 (1−); DENND1B (1+); LHX9 (1−)
2 COL4A3 2 COL4A3 (2−)
4 COL8A1 3 NIT2 (5−); TBC1D23 (4−); RP11.114I8.4 (2+); TOMM70A (2+); TMEM45A (1−)
5 CFI 4 PLA2G12A (13+); CASP6 (3+); CCDC109B (1−); CFI (1−)
9 VEGFA 6 PPP2R5D (2−)
11 PILRB/PILRA 7 STAG3L5P (27+); PILRB (27+); PILRA (26+); PMS2P1 (14−); TSC22D4 (8+); ZCWPW1 (3+); NYAP1 (3−); ZKSCAN1 (1−); STAG3 (1−)
10 KMT2E/SRPK2 7 RP11.325F22.5 (1+); RP11.325F22.2 (1+)
12 TNFRSF10A 8 TNFRSF10A (14−)
14 TRPM3 9 TRPM3 (1+)
13 MIR6130/RORB 9 RORB (1−)
15 TGFBR1 9 TGFBR1 (1+)
18 ARMS2/HTRA1 10
PLEKHA1 (17−/1+); BTBD16 (11+/ 3−); ARMS2 (14−); HTRA1 (5+/ 2−); DMBT1 
(3−); ATE1 (2+); RP11.318C4.2 (2−); FGFR2 (1−); TACC2 (1−); RP11.107C16.2 (1−); 
RP11.564D11.3 (1+); IKZF5 (1−); ACADSB (1−)
19 RDH5/CD63 12 RDH5 (17−); BLOC1S1 (1+)
21 B3GALTL 13 B3GALTL (5+)
22 RAD51B 14 PLEKHH1 (2+)
23 LIPC 15 ALDH1A2 (1+); LIPC (1+)
24 CETP 16 CETP (4−); HERPUD1 (2−); NLRC5 (2−); MT1DP (1+); GPR56 (1−)
25 CTRB2/CTRB1 16 CFDP1 (4−); BCAR1 (2−); TMEM170A (2+)
26 TMEM97/VTN 17 TMEM199 (10+); POLDIP2 (3+); TMEM97 (2+)
27 NPLOC4/TSPAN10 17 C17orf70 (1+); NPLOC4 (1+); PDE6G (1−)
29 CNN2 19 MED16 (3+); GRIN3B (2−); ABCA7 (2−); AC006273.5 (1+); CNN2 (1−)
28 C3 19 GPR108 (22+); CTC.503J8.6 (1−); GTF2F1 (1−)
30 APOE 19 RELB (1−); BLOC1S3 (1+); DMPK (1+)
31 MMP9 20 PLTP (10+); SLC12A5 (8−/1+); SPATA25 (1+); NEURL2 (1+)
34 SLC16A8 22 BAIAP2L2 (2−); PICK1 (1−); CBY1 (1−)
Table 1. AMD-associated genes located in known AMD loci. aAMD locus number and name according to 
Fritsche et al.2. bAMD-associated genes in TWAS analysis overlapping with the locus of Fritsche et al. (2016) 
(ref. 2) in a +/− 1 Mb window. cPositive effect direction (+) points to predicted gene expression being higher in 
AMD cases compared to controls and vice versa for negative effect direction (−). Chr = Chromosome.
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protein 1 using 11-cis-retinaldehyde or 11-cis-retinal as physiologic ligands. Two transcripts (PARP12 and CTA-
228A9.3) have not been characterized so far.
AMD-associated genes overlapping pleiotropic loci. More than half of the AMD-associated genes 
identified in this study (54/106) show a significant effect in multiple tissues and are not retina-specific. In addi-
tion, our network analysis demonstrates an enrichment of systemic processes such as an involvement in the 
complement cascade and the lipid metabolism. This raises the question whether AMD-associated genes may also 
be involved in the pathomechanisms of other complex diseases. We therefore expanded the study of Grassmann 
et al. (2017) and investigated a total of 91 GWAS studies covering 82 complex traits and diseases (Supplementary 
Table S4a)16. First, we extracted the genome-wide significant independent lead variants (P-value ≤ 5 × 10−8) for 
each complex trait or disease and added information about variants in LD from the 1000 G reference data (Fig. 3). 
Next, we defined R2 loci for each GWAS lead variant by summarizing all variants in LD (R2 > 0.5). Overlapping 
loci of different traits were merged to one larger locus. In classical GWAS approaches, genes in direct proxim-
ity to the lead variant are a priori candidate gene in the sense that such a gene gains high priority in having a 
functional role in the disease process. For this reason, we identified genes overlapping with R2 loci and termed 
them potentially pleiotropic if the corresponding locus included lead variants of different complex traits and 
diseases. In a first approach, we added a window of additional 1 Mb up- and downstream to each R2 locus in line 
with Predixcan, which also includes genetic variants within this range around genes8. We then merged over-
lapping 1 Mb loci and determined how many of the 106 AMD-associated genes were located within these loci. 
Altogether, 105 genes intersected with at least a single 1-Mb-locus. A total of 102 genes were potentially pleio-
tropic (Supplementary Table S4b). Additionally, 18,813 (77.14%) of the 24,388 predictable genes unique in at least 
one tissue were also located in these 1-Mb-loci. Such an outcome was due to the extensive size of the constructed 
loci (mean size: 4286.5 kb; SD: 2778.7) and made result interpretation inaccurate.
We therefore decided to generate R2 loci (mean size: 143.1 kb; SD: 208.7) for further analysis. Some of the 
investigated traits shared variants due to the fact that the traits were exploring the same higher-level pathway as 
was the case for high-density lipoprotein (HDL) and low-density lipoprotein (LDL). To circumvent this issue, 
we manually assembled the 82 complex traits and diseases into 13 categories, such as complex eye diseases and 
traits, AMD, autoimmune diseases, cancer, cardiovascular diseases, metabolic traits, neurological diseases and 
others (Supplementary Table S4a). A total of 50 AMD-associated genes (47.17%) overlapped with at least one 
disease group R2 locus, including 23 genes, which were potentially pleiotropic (Fig. 4A). Regarding all 24,388 
unique predictable genes, 3,846 (15.77%) overlapped with an R2 locus. It is important to note that not all of the 
88 AMD-associated genes in the reported AMD loci (Table 1) were also located within the R2 loci of the AMD 
category. This is due to variants included into PrediXcan’s prediction models expanding up to one Mb to each side 
of the start and end of a gene. Interestingly, genes which overlap with at least one R2 locus are AMD-associated 
in more tissues than genes which are not localized within such a locus (Mann-Whitney-U-Test P-value 0.0053) 
(Fig. 4B). Altogether, the 50 AMD-associated genes which are positioned in a GWAS locus of at least one trait 













AMD associated (GWAS 
P-value < 1 × 10-04)b
C1orf21 1 15 1 −0.028 Liver 34 3
CD55 1 17 3 −0.016 (0.003) Esophagus Muscularis 59 5
CR2 1 3 1 −0.013 Muscle Skeletal 40 6
NOSTRIN 2 18 1 −0.015 Esophagus Mucosa 44 0
PPIL3 2 27 16 0.037 (0.004) Adipose Subcutaneous 37 24
NDUFB3 2 6 4 0.005 (0.001) Adipose Subcutaneous 12 8
ADAM19 5 21 12 −0.013 (0.006) Adipose Subcutaneous 25 8
IP6K3 6 17 1 0.019 Cells Transformed fibroblasts 22 1
ZFP37 9 10 1 −0.017 Adipose Subcutaneous 53 0
RP11.777F6.3 11 2 1 0.007 Testis 5 2
CEP57 11 23 3 −0.02 (0.005) Skin Not Sun Exposed Suprapubic 48 0
AP001877.1 11 24 8 −0.016 (0.006) Nerve Tibial 50 0
RIN3 14 13 1 0.018 Colon Sigmoid 24 2
ULK3 15 17 1 −0.01 Lung 10 4
USP7 16 3 1 0.014 Muscle Skeletal 55 1
FUT2 19 11 1 −0.009 Lung 23 0
MAMSTR 19 9 1 0.007 Adrenal Gland 13 0
LILRA3 19 23 1 −0.016 Colon Sigmoid 15 2
Table 2. AMD-associated genes located in novel loci that did not reach genome-wide significance in previous 
GWAS studies2. aTissue, which showed the highest absolute effect size. bNumber of variants in prediction 
model, which were AMD-associated with a p-value smaller than 1 × 10−04 in Fritsche et al. (2016) (ref. 2). 
Chr = Chromosome.
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multiple groups (Fig. 4C). To test, if this overlap with R2 loci of complex traits or diseases is by chance only, we 
applied Fisher’s exact test for count data using contingency tables including the 106 AMD-associated genes and 
the list of all 24,388 unique predictable genes.
Overall, 15 AMD-associated genes overlap with R2 loci of neurological diseases (P-Value 7.65 × 10−7), 10 genes 
with metabolic traits (P-Value 0.042) and nine genes with autoimmune diseases (P-Value 0.044). Furthermore, 
six genes share loci also associated with cancer (P-Value 0.076) and five genes intersect with loci significantly 
associated to organ function (P-Value 0.018) (Fig. 4C). These data point to systemic and pleiotropic processes 
in which AMD-associated genes may be involved. Remarkably, only two out of 106 AMD-associated genes are 
linked to loci of complex eye diseases and traits, namely RDH5 and COL4A3. Almost one quarter (21.7%) of all 
AMD-associated genes identified in this study overlap with R2 loci of two or more complex traits and diseases 
(Table 3). Three AMD-associated genes (BCAR1, CFDP1, and TMEM170A) residing within a locus on chromo-
some 16 (chr16:75233867-75516739), coincide with GWAS signals of six different trait groups, namely “organ 
function”, “cancer”, “neurological diseases”, “autoimmune diseases”, “metabolic traits”, and “AMD”.
Discussion
We performed a TWAS based on the individual data of 16,144 late-stage AMD cases and 17,832 non-AMD con-
trols to further explore causative genes and pathways involved in AMD-associated processes. We predicted gene 
expression in 27 different tissues and identified 106 genes with significant association to late stage AMD status. 
An enrichment analysis revealed a significant accumulation of genes involved in the complement cascade and 
lipid metabolism. For example, gene expression of CFH and CFI, both regulators of the alternative complement 
pathway, was found AMD-associated in our study with negative effect sizes suggesting that the expression of these 
genes is lower in AMD cases than in controls. Consistent with this are earlier findings demonstrating lower com-
plement Factor H (encoded by the CFH gene) levels in the sera of AMD patients18–20. Furthermore, the expression 
of negative regulators of CFH, specifically CFHR1, CFHR3, and CFHR4, is predicted to be upregulated in AMD 
cases, which consequently should lead to an increased complement activation.
Figure 2. Enriched GO biological processes in 106 genes identified (adjusted P-value < 0.05). Enrichr was 
used to assign gene ontology (GO) terms for the 106 AMD-associated genes and to investigate enriched GO 
biological processes60. The eight significantly enriched processes are shown, clustered into the complement 
cascade and lipid-related processes. Genes are given for each process. Genes colored in green indicate those 
which were not identified previously in AMD-associated loci.
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Our study also identified two genes (CD55 and CR2) in loci, which failed to reach genome-wide signifi-
cance in previous AMD GWAS2,21 Interestingly, the prediction models of both genes included variants which 
were AMD-associated in the latest AMD GWAS but below the threshold for suggestive association (GWAS 
P-value < 1 × 10−04)2 (Table 2). CD55 and CR2 are both predicted to be expressed at a lower level in AMD cases 
compared to controls. CD55 inhibits the C3-convertase and consequently regulates activity of the complement 
system22. Interestingly, homozygous mutations in CD55, known to results in loss-of-function, have been found 
in patients suffering from complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 
(MIM 226300)23. While two studies measured CD55 expression in blood cells of AMD patients, they consistently 
failed to observe significant differences compared to healthy individuals24,25. This is well in line with our cur-
rent study which predicts CD55 expression to be AMD-associated exclusively in “Esophagus Muscularis”, “Heart 
Atrial Appendage”, and “Nerve Tibial”, but not in “Whole Blood”.
CR2 is a member of the complement activation regulator family and plays a role in the humoral immune 
response26. Polymorphisms in CR2 have been associated with susceptibility to systemic lupus erythematosus 
type 9 (MIM 610927)27. It is important to note that the models used for gene expression prediction in our study 
were based on normal tissue and therefore likely reveal general effects of gene expression regulation based on the 
respective genetic background. In general, our findings relating to complement genes support the hypothesis that 
the complement system is more active in AMD cases than in control individuals. It can be expected that such 
effects are occurring throughout an entire lifetime well before AMD manifestation. However, gene expression in a 
diseased tissue may ultimately be unpredictable and significantly different from gene expression in healthy tissue.
The second major finding evident from our list of 106 AMD-associated genes points to lipid metabolism path-
ways. LIPC encodes a protein called hepatic lipase (HL) and is AMD-associated exclusively in liver tissue. HL is 
secreted into the bloodstream regulating HDL concentration. Lower HL activity was observed to result in higher 
HDL levels in blood28. Our study predicted a higher gene expression of LIPC in AMD cases, which then would 
be expected to result in lower blood HDL levels. This is consistent with an earlier mega-analysis of eQTL in liver 
tissue which included four independent studies5.
Higher levels of HDL were shown in multiple studies to be associated with elevated AMD risk29–31. Our data 
suggest that lower predicted CETP expression is significantly associated with AMD in four tissues, but not in 
liver. As CETP deficiency leads to high HDL levels, this fits earlier findings, that increased HDL is associated with 
AMD risk32,33.
The plasma phospholipid transfer protein (PLTP), encoded by another lipid related gene was AMD-associated 
in 10 out of 27 tissues and showed a mean effect size of 0.017 (SD: 0.006). Interestingly, PLTP was not associ-
ated with AMD in a previous GWAS but is located in AMD locus 312. PLTP facilitates the transfer of phos-
pholipids and cholesterol in-between lipoproteins. Reduced plasma PLTP activity was shown to cause markedly 
decreased HDL levels34,35. It also plays a role in inflammatory processes and participates in the etiology of 
atherosclerosis36,37. Remarkably, increased PLTP levels in plasma were identified as potential biomarker for 
AMD in a proteomics-based approach38. ABCA7, a gene also involved in lipid metabolism, was significantly 
AMD-associated in our study in lung and whole blood tissue. There is strong evidence that mutations in ABCA7 
are involved in Alzheimer disease (AD-9) (MIM 608907)39,40.
Figure 3. Work-flow for identification of pleiotropic genes. Genome-wide significant independent GWAS 
signals (P-value ≤ 5 × 10−8) were extracted for 82 complex traits and diseases from the corresponding 
publications. Additionally, variants in LD for each of the independent GWAS hits were included in the 
analysis. Linked variants with R2 > 0.5 demarcated the start- and stop-positions for a GWAS signal R2 Locus. 
Overlapping loci were merged to identify potential pleiotropic genomic regions. The genes overlapping with at 
least one R2 locus were identified.
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Taken together, two major pathways related to AMD pathogenesis, including complement activation and 
lipid-related processes, were identified through our gene enrichment analysis with both pathways well known 
in AMD research and thus greatly increasing confidence in the robustness of our data. It is of interest to note 
that the two pathways are the only significant findings in our study suggesting that the majority (96/106) of 
AMD-associated genes may function in a plethora of different processes.
As AMD is a disease of the choroid/Bruch’s membrane/retinal pigment epithelium/photoreceptor complex, 
we conducted a separate TWAS based on retinal tissue6. Our initial expectation was to either find an enrichment 
of AMD-associated genes in the retinal tissue or to even identify a notable number of retina-specific genes impli-
cated in AMD etiology. 16 out of the 22 AMD-associated genes identified in retina by Ratnapriya et al.6 were also 
found in at least one non-retinal tissue in our study. This left six genes which potentially harbor a retina-exclusive 
effect. Remarkably, only one gene, namely RLBP1, reveals clear evidence to be causative for a disease of the retina 
such as Retinitis punctata albescens (MIM 136880) or rod-cone dystrophy (MIM 607476)41–43. Nevertheless, 
RLBP1 is expressed throughout all tissues of the human body10. Interestingly, a recent study regarding schizo-
phrenia, obviously a brain related disease, revealed that 51 (48.1%) of 106 schizophrenia-associated lead variants 
are eQTL in brain tissue44. In contrast, only 9 (17.3%) of the 52 AMD lead variants regulate gene expression in the 
retina6. This observation leads us to the conclusion that changes in retinal gene expression can only partly explain 
GWAS association signals and that retinal gene expression per se is not a suitable criterion to suggest relevance 
for AMD pathogenesis. Nevertheless, so far no gene expression regulation data of the retinal pigment epithelium 
Figure 4. Analysis of AMD-associated genes and their overlap with pleiotropic loci. (A) Number of genes, 
which overlapped with R2 loci of trait groups (B) Number of AMD-associated tissues per gene as identified by 
TWAS and overlap of genes with at least a single R2 locus (Mann-Whitney-U-Test P-value 0.0053) (C) Trait 
groups shared by AMD-associated genes identified in this study (black) and by all predictable genes (grey). 
The latter have been scaled from in total 24,388 to 106 genes to enable a better comparability. “Other” include 
“Aging”, “anthropometric traits”, “Blood cells”, “cardiovascular diseases”, “Complex eye diseases and traits”, 
“Lifestyle”, and “Immune-related traits”. Significance was assessed through a Fisher exact test. *P-value < 0.05; 
**P-value < 0.01; ***P-value < 0.001.
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(RPE) or the choroid tissue are available. Data about these tissues might enable further conclusions about gene 
expression regulation at primary sites of AMD pathology.
Genes significantly associated with AMD in a multitude of tissues, like STAG3L5P, PILRB, PILRA, GPR108, 
and CFHR3, are likely to act in systemic processes although disease expression appears to be restricted to the pos-
terior pole of the eye. Nevertheless, these genes may affect molecular processes possibly leading to other diseases 
besides AMD. This is supported by earlier studies associating the genetics of AMD with other complex traits 
and diseases16,45. Here, we analyzed the 106 AMD-associated genes for intersection with pleiotropic genomic 
regions identified as GWAS R2 loci for 82 complex traits and diseases. A striking 50 genes suggested in our study 
to have relevance to AMD pathology overlap with an R2 locus affecting at least one other complex trait or disease. 
It should be noted that co-localization within a shared genomic locus is not a functional evidence as such, but 
genes overlapping with a lead variant or a corresponding variant in high LD are a priori excellent candidate genes 
possibly playing a role in disease etiology. Remarkably, 15 genes are located in R2 loci of neurological diseases, 
including 8 genes related to AD, six genes in loci associated to migraine, and one gene overlapping a locus related 
to schizophrenia.
The findings in AD are of particular interest as AMD and AD share a number of similarities, particularly 
age-relatedness and pathological deposits in neurological tissue46. Correspondingly, beta-amyloid deposits, a hall-
mark of AD, are also found in retinal deposits of AMD, called drusen45,47. Our data point to two AD-related loci 
which contain AMD-associated genes. One is positioned on chromosome 19 and contains ABCA7, which was 
Gene Gene Type
AMD associated 
tissues (FDR < 0.001) Locus R2 [hg19] Disease groups in locus Single phenotypes in locus
BCAR1 Protein coding 2
chr16:75233867–75516739




FEV1FVC; LGF; PanC; MIG; 
T1D; T2D; AMDCFDP1 Protein coding 4
TMEM170A Protein coding 2
BAIAP2L2 Protein coding 2 chr22:38295271–38503972; chr22:38505356–38614129
AMD; Anthropometric 
traits; Metabolic traits; 
Cancer
AMD; BFP; TG; CMM
ALDH1A2 Protein coding 1 chr15:58671721–58692118; chr15:58718529–58742418
Blood cells; Metabolic 
traits; AMD
HB; RBC; HDL; TC; TG; 
AMD




DBP; GBP; HTN; SBP; SLE; 
MCV; RBC
COL4A3 Protein coding 2 chr2:228083236–228100488; chr2:228126494–228231432
AMD; Complex eye 
diseases and traits AMD; CCT
PMS2P1 pseudogene 14
chr7:99894971–100111776 Neurological diseases; AMD AD; AMD
STAG3L5P pseudogene 27
PILRB Protein coding 27
PILRA Protein coding 26
ZCWPW1 Protein coding 3
TSC22D4 Protein coding 8
NYAP1 Protein coding 3
RP11.325F22.2 lincRNA 1 chr7:104581402–105063372 AMD; Neurological diseases AMD; SCZ
PLEKHA1 Protein coding 18
chr10:124124669–124235355 Neurological diseases; AMD MIG; AMDARMS2 Protein coding 14
HTRA1 Protein coding 7
RDH5 Protein coding 17 chr12:56115585–56213297 AMD; Complex eye diseases and traits AMD; MYP
RIN3 Protein coding 1 chr14:93068516–93118229 Cancer; Organ function BRC; BRConly; FEV1; LGF
CETP Protein coding 4 chr16:56985514–57006829 AMD; Metabolic traits AMD; HDL; LDL; TC; TG
FUT2 Protein coding 1
chr19:49158532–49252574 Metabolic traits; Autoimmune diseases ALP; LEP; TC; CD; IBD; GGTMAMSTR Protein coding 1
Table 3. AMD-associated genes overlapping pleiotropic loci. AD = Alzheimers disease; ALP = LEP - alkaline 
phosphatase; AMD = Age-related macular degeneration; BCC = Basal cell carcinoma; BFP = Body fat 
percentage; BRC = Breast cancer - max. beta; BRConly = Breast cancer - only BRC; CCT = Central corneal 
thickness; CD = Crohns disease; CMM = Cutaneous malignant melanoma; CSCC = Cutaneous squamous 
cell carcinoma; DBP = Diastolic blood pressure; eGFR = estimated glomerular filtration rate of creatinine; 
FEV1 = forced expiratory volume in 1 second; FEV1FVC = forced expiratory volume in 1 second/forced 
vital capacity; GBP = General blood pressure; GGT = LEP - γ -glutamyl transferase; HB = Haemoglobin; 
HDL = High-density lipoprotein; HGT = Height; HTN = Hypertension; IBD = Inflammatory bowel disease; 
LDL = Low-density lipoprotein; LEP = Liver enzymes in plasma; LGF = Lung function; MCV = Mean cell 
volume; MIG = Migraine; MYP = Myopia; PanC = Pancreatic cancer; RBC = Red blood cell phenotypes; 
SBP = Systolic blood pressure; SCZ = Schizophrenia; SLE = Systemic lupus erythematosis; T1D = Type 1 
diabetes; T2D = Type 2 diabetes; TC = Total cholesterol; TG = Triglycerides.
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linked to both diseases in earlier studies40,48,49. The other locus is on chromosome 7 and contains several genet-
ically regulated genes which could be important for both diseases. These include the genes TSC22D4, NYAP1, 
PMS2P1, STAG3L5P, PILRB, PILRA, and ZCWPW1. Interestingly, some of these genes have already been investi-
gated in the context of AD50,51. Currently, it is not clear how the genes in this locus, which was first identified to be 
AMD-associated in 2016, contribute to AMD etiology2. It should be noted that one and the same locus is named 
differently in AMD- and AD-related research, namely PILRB-PILRA (AMD) or ZCWPW1 (AD)2,52.
Less is known about the six AMD-associated genes overlapping with an R2 locus of migraine. Interestingly, 
HTRA1 which is intensively investigated in AMD is mutated in CARASIL syndrome (MIM 600142), the latter 
known to be preceded by migraine53,54. Furthermore, 10 AMD-associated genes overlap with R2 loci of metabolic 
traits and 9 genes intersect with GWAS loci involved in autoimmune diseases. Both findings are in line with our 
gene enrichment analysis and are intensely discussed in current research11,12,30,55. Noteworthy, our results do not 
support the previously identified genetic relationship of AMD and cardiovascular disease (CAD), as only a single 
AMD-associated gene (ULK3) overlaps with an R2 locus of CAD16,56. However, this does not preclude the possi-
bility that genetics of AMD and CAD may be linked due to effects other than gene expression regulation. Finally, 
a remarkable observation is that our analysis identified only two genes, namely RDH5 and COL4A3, which over-
lap with GWAS loci of complex eye diseases and traits except AMD. Unfortunately, drawing conclusions on the 
direction of effects remains challenging due to the fact that our findings are based on genomic positions and 
GWAS signals.
In conclusion, genetically based regulatory effects on gene expression represent a lifetime influence. Our 
TWAS study identified 106 genes with expression predicted to be AMD-associated in at least one of 27 tissues. 
The disease-associated expression of genes points to various pathways and mechanisms potentially relevant for 
AMD etiology and other overlapping complex traits and diseases. Future studies, searching for AMD treatment 
options or for strategies to prevent AMD, should therefore strongly consider that AMD-associated genetics sug-
gests to alter gene expression throughout the whole body and that these mechanisms are likely involved in a 
spectrum of other common diseases of mankind.
Methods
Study samples and genotype data. The genotypes and phenotypes from 33,976 individuals with 
European ancestry were retrieved from the IAMDGC consortium (see “Data availability statement”). We included 
the genotypes from 16,144 late-stage AMD cases, presenting with geographic atrophy and/or choroidal neovas-
cularization, and from 17,832 AMD-free control individuals. Detailed inclusion and exclusion criteria as well 
as comprehensive information about genotype quality control and imputation procedure are given elsewhere2. 
For gene expression imputation, we used the genotype information of 11,722,957 autosomal genetic variants. As 
PrediXcan does not accept missing values, genotypes have been transformed to an allele dosage format and miss-
ing genotypes of single individuals were filled by the most frequent corresponding genotype.
TWAS analysis. We used the PrediXcan algorithm to predict gene expression based on genotype informa-
tion8. Gamazon et al. provided prediction models (available through PredictDB; http://predictdb.org/) trained 
on the data of European individuals within the GTEx Version 7 release (GTEx-V7_HapMap-2017-11-29.tar.
gz)57. For 27 of 48 tissues, genotype and gene expression data of more than 130 individuals (between 134 and 
421) were available for prediction model building (Supplementary Table S1a). We applied PrediXcan for each of 
these 27 tissues to predict individual level gene expression of the IAMDGC cohort. We then used R58 to calculate 
the linear regression of predicted gene expression with AMD and control status. Additionally, we adjusted the 
model for gender, age and the first two principal components of the genotype PCA performed by Fritsche et al2. 
To account for multiple testing, we adjusted the P-values of all 181,536 tests using the false discovery rate (FDR)59. 
Genes located within the major histocompatibility complex (MHC) locus (chr6: 28,477,797–33,448,354, hg19) 
were excluded from our analysis due to its highly complex association structure. Remaining genes with a Q-value 
smaller than 0.001 were considered to be significantly AMD-associated.
Network analysis. Enrichr was used to assign gene ontology (GO) terms to our list of AMD-associated 
genes and to investigate enriched GO biological processes60.
Identification of pleiotropic loci. We investigated AMD-associated gene intersections with loci, which are 
known to be associated with other complex traits and diseases. To this end, we searched PubMed (www.pubmed.
gov) for GWAS of human traits and diseases, which (1) included primarily individuals of European descent 
and (2) were published prior to November 2016. Detailed inclusion and exclusion criteria for GWAS studies 
are given elsewhere16. After quality control, we included 82 different traits and diseases into our further analysis 
(Supplementary Table S4a,c). We extracted the genome-wide significant (P-value ≤ 5 × 10−8) and independent 
GWAS signals and extended them by extracting variants in LD using the 1000 G reference data61. The entirety 
of linked variants (R2 > 0.5) was used to define start- and stop-positions for every GWAS signal R2-Locus. Next, 
we merged overlapping loci to identify potential pleiotropic genomic regions. We then extracted all ensemble 
annotated genes and annotations (version 90)62 and mapped them to the beforehand identified trait-associated 
loci. Each gene was subsequently assigned to the corresponding trait if the genomic position overlapped to the 
R2-Loci.
Statistical evaluation. All bioinformatical analysis steps were conducted using either the Unix command 
line or the R programming language. Gene expression imputation based on genotypes of the IAMDGC dataset 
was performed via PrediXcan. PrediXcan applied LASSO, elastic net and the simple polygenic score based on all 
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tissues of the GTEx project to generate a gene expression prediction model for each gene per tissue. Details about 
the model building process and the quality control measures are given elsewhere8. After gene expression impu-
tation for each of the 27 investigated tissues, we applied a linear regression model to correlate gene expression 
with AMD status. Thereafter, we adjusted P-values for multiple testing using a stringent FDR setting. The number 
of investigated genes per tissue and accordingly the number of conducted tests are shown in Supplementary 
Table S1a. We chose a Q-value threshold of 0.001 to minimize the probability to identify false positive genes. A list 
of all significantly AMD-associated genes (Q-value < 0.001) is provided in Supplementary Table S1b.
For the network analysis, Enrichr outputs an adjusted p-value to evaluate significance of enriched processes. 
This is based on a score calculated by multiplying the log p-value computed by the Fisher exact test with the 
z-score of the deviation from the expected rank by the Fisher exact test60.
To determine the significance of the overlap of AMD-associated genes with the R2 loci, we applied Fisher’s 
exact test for count data based on the gene list of interest in comparison to all 24,388 unique predictable genes in 
at least one tissue outside the MHC locus. This was achieved by creating contingency tables and analyzing them 
with the fisher.test function in R.
Ethics approval and consent to participate. Twenty six international study groups contributed DNA 
samples from a total of 33,976 individuals with and without AMD disease (IAMDGC), as previously described2. 
Approval was obtained from each participating site by their respective local ethics review board and informed 
written consent was obtained from each patient2. At each site, the study strictly adhered to the tenets of the 
Declaration of Helsinki.
Consent for publication. Not applicable.
Data availability
The dataset used in this study was retrieved from the IAMD consortium and compiled information from 
16,144 people with late-stage AMD and 17,832 control individuals without AMD. Data permitted for sharing 
by respective institutional review boards (13,379 late stage AMD subjects and 16.246 AMD-free controls) are 
available at the database of genotypes and phenotypes (dbGaP)63 under the accession number phs001039. 
Publicly available data from genome-wide association studies (GWAS) of human diseases and traits were 
extracted from the respective publications. The relevant PubMed identifiers of those publications are listed in 
Supplementary Table S4a. The prediction models for gene expression imputation are available through PredictDB 
(http://predictdb.org).
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